When the system says “wait,” some people start building
Some stories do not merely inspire.
They expose an entire sector.
Not with a slogan.
Not with a glossy conference.
With urgency.
In the materials he has made public, Sid Sijbrandij says that at the end of 2022 he went to the emergency room with pain, that doctors found a 6 cm tumor growing from his spine, and that in 2023 he was diagnosed with high-grade osteosarcoma. He then went through standard-of-care treatment including surgery, radiation, and intensive chemotherapy. According to the National Cancer Institute, localized osteosarcoma is indeed typically treated with surgery, chemotherapy, and sometimes radiation therapy.
Then came the break.
After two years of remission, he describes a local progression in 2024 and condenses the turning point into one chilling line: “You’re done with standard of care. Good luck!” In his own telling, that is the moment he stopped behaving like a passive patient waiting for the system to run its sequence and started acting like a founder rebuilding the operating model around survival.
That shift deserves the attention of every executive.
Because at that moment, he does not simply seek another treatment.
He redesigns the decision process itself.
He measures more.
He tests more.
He opens more options.
He accelerates.
And suddenly, what many companies still call innovation starts to look like theatre. (Sytse, Century of Bio)
Founder mode applied to survival
In his presentation, Sid Sijbrandij frames his approach around four pillars: maximal diagnostics, making treatments, treatments in parallel rather than serial, and scaling for others. He also states that he has made 25 TB of data publicly available through osteosarc.com, and he describes an approach involving DNA/RNA sequencing, single-cell sequencing, frequent MRD testing, targeted radiodiagnostics, and more than 10 personalized drugs and diagnostics. The National Cancer Institute defines precision medicine as medicine that uses information about a person’s genes, proteins, environment, and lifestyle, and in cancer specifically about the tumor, to guide diagnosis, treatment, monitoring, and prognosis.
What stands out here is not only medical complexity.
It is the mental architecture.
Many organizations still operate like a queue:
observe first,
validate later,
test eventually,
deploy one day,
learn when the window has almost closed.
He operates differently:
multiply signals,
expand optionality,
reduce blind spots,
reject the single-scenario mindset,
treat time as a strategic variable.
In my book, chapter 17, I explain that biohacking rests on vision, methods, experiments, and learning. This story reads like a full-scale demonstration of that principle.
What this reveals about modern medicine
This story does not prove that every patient can or should replicate such an approach.
It reveals something else.
It reveals what becomes visible when the stakes turn existential: fragmentation, sequential logic, administrative drag, information asymmetry, and limited access to experimental options.
The FDA itself states that expanded access may be appropriate when a patient has a serious or immediately life-threatening disease, no comparable or satisfactory alternative exists, clinical trial enrollment is not possible, and the potential benefit justifies the potential risk. The agency also describes the single-patient IND pathway for individual patients.
In other words, even regulators acknowledge that the default system does not cover every urgent human reality.
What Sid’s story puts on the table is the gap between a system designed for average safety and a life that is singular, time-constrained, and deeply personal.
That gap is not unique to medicine.
It appears anywhere institutions are optimized to administer the normal while reality demands faster action on the exceptional.
The deadly trap of sequential thinking
One of the strongest ideas in his presentation is brutally simple: “Treatments in Parallel, Not Serial.” He also writes that many people run out of time before finding a cure and that there is no real incentive to test treatments together. Whether one agrees with every implication or not, the management lesson is huge: in some situations, the order of testing is itself a strategic risk.
That is exactly what many companies still fail to understand.
They think they are reducing risk by sequencing everything.
What they actually do is relocate the risk.
They reduce internal decision discomfort.
They increase external obsolescence risk.
They protect process.
They lose tempo.
And tempo now matters everywhere:
AI, biotech, energy, defense, media, education, finance, healthcare.
The danger is no longer only being wrong.
The danger is understanding too late.
Open data, open options
Another signal matters: data openness.
Sid points publicly to osteosarc.com and to a large openly readable dataset. That logic aligns with the broader stance of the NIH, which states that sharing scientific data accelerates biomedical research discovery, improves rigor and reproducibility, increases access to high-value datasets, and promotes reuse in future studies.
This is where many organizations are still trapped in contradiction.
They talk about collaboration.
They keep data in silos.
They talk about transformation.
They let critical information sleep.
They talk about faster decisions.
They make access to reality painfully slow.
The moment an organization closes the flow of information, it also closes the field of options.
And once optionality narrows, speed becomes a slogan instead of a capability.
The message executives should not ignore
The point is not that companies should “play doctor.”
The point is to understand what this story makes impossible to ignore.
An effective founder does not worship protocol.
He respects rigor.
He still questions the order of operations.
He seeks the best real path, not the default administrative path.
That is where many leadership teams fail.
They believe they are managing innovation because they fund a few pilots, open a lab, launch a committee, invite a couple of experts, and ask for quarterly reporting.
Meanwhile, weak signals accumulate.
Competitors experiment.
Customers shift.
Usage changes.
Markets rewrite the rules.
And the company remains busy asking permission to look.
What organizations should copy immediately
Not the medical condition.
Not the suffering.
Not the biography.
The operating frame.
Capture more useful signals.
Create more options instead of defending one hypothesis.
Accept that some experiments must run in parallel.
Move data faster.
Decide before bureaucratic comfort reaches perfection.
The OECD definition is useful here: innovation is not a decorative idea. It is a new or improved product or process that has been made available to users or brought into use. Innovation begins at implementation, not at commentary.
That is why this story extends far beyond medicine.
It points toward the next frontier of management: decisions strengthened by data, experimentation, and coordinated action.
The future will not belong to the most cautious structures
It will belong to the structures capable of being rigorous without becoming immobile.
Useful caution measures better.
Toxic caution delays everything.
The first protects the future.
The second mostly protects habits.
Your next doctor may not literally be a founder.
But many leaders will have to learn to think as if their organization depended on the same level of strategic intensity.
Because in every sector, sooner or later, reality enters the room and says:
the standard of care is no longer enough.
From that moment on, two kinds of organizations separate.
Those waiting to be saved.
And those building their odds.
References
(Sytse) = https://sytse.com/cancer/
(Century of Bio) = https://centuryofbio.com/p/sid
(Osteosarc) = https://osteosarc.com/
(National Cancer Institute – Precision Medicine) = https://www.cancer.gov/publications/dictionaries/cancer-terms/def/precision-medicine
(National Cancer Institute – Osteosarcoma Treatment PDQ) = https://www.cancer.gov/types/bone/hp/osteosarcoma-treatment-pdq
(FDA – Expanded Access) = https://www.fda.gov/news-events/public-health-focus/expanded-access
(FDA – Single Patient Expanded Access) = https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use
(NIH – Scientific Data Sharing) = https://osp.od.nih.gov/policies/scientific-data-management-policy/
(OECD) = https://www.oecd.org/en/publications/oslo-manual-2018_9789264304604-en.html
